Introduction {#sec1}
============

Tuberculosis, caused by the bacterium *Mycobacterium tuberculosis*, is a major source of morbidity and mortality worldwide with almost two million deaths annually, and the rise in multidrug resistant and extensively drug resistant strains is of great concern.^[@ref1]−[@ref3]^ There is thus considerable interest in the development of new drugs and new leads such as SQ109 and TMC-207,^[@ref4]^ which target cell wall biosynthesis and ATP formation, respectively, and also in the development of new therapeutic approaches that target virulence factor (VF) formation. VFs are by definition not essential for bacterial growth outside of host cells but are involved in processes such as invasion, persistence, lysis, and evasion of innate immune system responses, as found for example with staphyloxanthin in *Staphylococcus aureus*.^[@ref5],[@ref6]^ This carotenoid VF provides resistance to host-based reactive oxygen species-based killing, and inhibiting staphyloxanthin biosynthesis is a novel route to anti-infective therapy.^[@ref6]^ In *M. tuberculosis*, one class of VFs are the tuberculosinols:^[@ref7]−[@ref9]^ tuberculosinol (TOH) and the (±)-*iso*-tuberculosinols (*iso*-TOH), Scheme [1](#sch1){ref-type="scheme"}. The latter were first isolated from a marine sponge from the Nosy Be island, Madagascar, and are thus also known as (±)-nosyberkols^[@ref10]^ (Scheme [1](#sch1){ref-type="scheme"}). The original structures proposed^[@ref7]−[@ref10]^ have been confirmed by total synthesis.^[@ref11],[@ref12]^ The biosynthesis of the tuberculosinols is catalyzed by two enzymes: Rv3377c, tuberculosinyl (halama-5,13-dien-15-yl) diphosphate synthase, and Rv3378c, tuberculosinol/(±)-*iso*-tuberculosinol synthase (Scheme [1](#sch1){ref-type="scheme"}). Both proteins are essential for bacterial survival inside macrophages^[@ref13]^ with the tuberculosinols inhibiting phagolysosome maturation as well as macrophage phagocytosis.^[@ref8],[@ref9],[@ref14]^ Thus, the three-dimensional (3D) structures of both Rv3377c and Rv3378c are of considerable interest since they are thought to represent novel antivirulence therapeutic targets for tuberculosis.^[@ref15]^ Rv3377c is a diterpene cyclase that converts geranylgeranyl diphosphate (GGPP) into tuberculosinyl diphosphate (TPP), while Rv3378c converts TPP into TOH and the *iso*-TOHs, acting as a phosphatase/isomerase, as shown in Scheme [1](#sch1){ref-type="scheme"}. Here, we report the structure of Rv3378c both in its apo form as well as bound to its TPP substrate, and to a bisphosphonate inhibitor, BPH-629 (Scheme [1](#sch1){ref-type="scheme"}). We also report the structure of the *M. tuberculosiscis*-decaprenyl diphosphate synthase (Rv2361c) with another bisphosphonate inhibitor, BPH-640 (Scheme [1](#sch1){ref-type="scheme"}), which has a similar structure and inhibitor-binding mode as those found with Rv3378c, the phosphatase.

![Biosynthesis of *Mycobacterium tuberculosis* virulence factors (tuberculosinols) and decaprenyl diphosphate, which is essential for cell wall biosynthesis](ja-2013-13127v_0005){#sch1}

###### Data collection and refinement statistics for the Rv3378c crystals. Values in parentheses are for the outermost resolution shells

                              Rv3378c native 1       Rv3378c native 2       Rv3378c Y51F with TPP   Rv3378c Y51F/Y90F with TPP   Rv3378c with 629       Rv2361c with 640
  --------------------------- ---------------------- ---------------------- ----------------------- ---------------------------- ---------------------- --------------------
  Data Collection                                                                                                                                       
  resolution (Å)              25.0--2.3 (2.4--2.3)   25.0--2.1 (2.2--2.1)   25.0--2.7 (2.8--2.7)    25.0--2.4 (2.5--2.4)         25.0--2.1 (2.2--2.1)   50--1.8 (1.9--1.8)
  space group                 *P*4~3~2~1~2           *C*2                   *P*4~3~2~1~2            *P*4~3~2~1~2                 *P*4~3~2~1~2           *P*2~1~2~1~2~1~
  unit cell                                                                                                                                              
  *a* (Å)                     105.9                  208.4                  106.5                   106.3                        105.4                  77.8
  *b* (Å)                     105.9                  56.5                   106.5                   106.3                        105.4                  89.2
  *c*(Å)                      66.6                   114.4                  66.4                    66.8                         66.0                   93.9
  β (deg)                     90.3                   90.3                   90.3                    90.3                         90.3                   90.0
  no. of unique reflections   18334 (1794)           77301 (6681)           11190 (1049)            15419 (1505)                 21574 (2082)           58370 (2875)
  redundancy                  7.9 (8.1)              3.9 (2.7)              7.2 (7.7)               10.3 (10.6)                  10.2 (10.2)            14.8 (14.8)
  completeness (%)            99.9 (100.0)           98.1 (85.6)            99.3 (96.8)             99.7 (100.0)                 99.3 (97.6)            100.0 (100.0)
  mean *I*/σ(*I*)             43.6 (6.5)             19.2 (2.3)             47.1 (3.6)              37.2 (4.3)                   52.4 (6.4)             41.6 (3.4)
  *R*~merge~ (%)              5.0 (43.3)             6.5 (41.6)             5.6 (39.1)              6.5 (52.1)                   5.3 (39.7)             7.8 (69.4)
  Refinement                                                                                                                                             
  no. of chain(s)             1                      4                      1                       1                            1                      2
  no. of reflections          17676 (1634)           65562 (2237)           10756 (946)             14914 (1326)                 20950 (1961)           55357 (3783)
  *R*~work~ (95% of data)     0.212 (0.250)          0.198 (0.222)          0.240 (0.342)           0.231 (0.293)                0.197 (0.242)          0.157 (0.227)
  *R*~free~ (5% of data)      0.239 (0.308)          0.239 (0.302)          0.261 (0.365)           0.260 (0.363)                0.237 (0.243)          0.198 (0.294)
  rmsd bonds (Å)              0.007                  0.006                  0.006                   0.008                        0.008                  0.025
  rmsd angles (deg)           1.3                    1.2                    1.3                     1.2                          1.4                    2.4
  Ramachandran Plot (%)                                                                                                                                 
  most favored (%)            95.1                   96.3                   94.4                    94.7                         96.9                   94.0
  allowed (%)                 4.9                    3.7                    5.6                     5.3                          3.1                    5.8
  disallowed (%)              0.0                    0.0                    0.0                     0.0                          0.0                    0.2
  mean *B* (Å^2^) /atoms      55.2/2611              28.6/10274             89.0/2520               55.7/2444                    46.8/2757              26.9/4510
  PDB ID code                 3WQK                   3WQL                   3WQN                    4KT8                         3WQM                   4ONC

Materials and Methods {#sec2}
=====================

Full details are given in the [Supporting Information](#notes-1){ref-type="notes"} (SI) online.

Result and Discussion {#sec3}
=====================

We cloned, expressed, purified, crystallized, and solved the Rv3378c protein structure by using multiple isomorphous replacement in a tetragonal crystal and then by using molecular replacement in a monoclinic crystal, Table [1](#tbl1){ref-type="other"} and Table S1 in the [SI](#notes-1){ref-type="notes"}. Residues 46--50 could not be modeled in one crystal, or 82--90 in another, due to lattice packing and disorder. Nevertheless, the two structures superimposed well, and a continuous protein dimer model could be constructed (Figure [1](#fig1){ref-type="fig"}a and Figure S1a in the [SI](#notes-1){ref-type="notes"}), consistent with the observation that Rv3378c also exists as a dimer in solution.^[@ref9]^ The overall fold shows close structural homology to that seen in *M. tuberculosiscis*-farnesyl diphosphate synthase (Rv1086; 2.33 Å Cα rmsd over 201 residues; PDB ID code 2VFW), *M. tuberculosis* decaprenyl diphosphate synthase (Rv2361; 2.23 Å over 195 residues; PDB ID code 2VG4), and *E. coli* undecaprenyl diphosphate synthase (UPPS; 2.44 Å over 203 residues; PDB ID code 1JP3), although there is only ∼12--14% sequence identity with these proteins.

![Structures of tuberculosinol/(13*R*,*S*)-*iso*-tuberculosinol synthase (Rv3378c) and undecaprenyl diphosphate synthase (UPPS). (a) Rv3378c dimer. Both N- and C-termini of both monomers locate at the top of the dimer structure. (b) Predicted Rv3378c ligand binding site. (c) *Escherichia coli* UPPS ligand binding sites (PDB ID code 2E98). Electrostatic surfaces are shown for Rv3378c and UPPS cavities, colored blue in positive region, red in negative region, calculated using PyMOL.](ja-2013-13127v_0002){#fig1}

There is a potential substrate-binding site at the "top" of the structure (Figure [1](#fig1){ref-type="fig"}b and Figure S1b in the [SI](#notes-1){ref-type="notes"}), but this cavity^[@ref16]^ is smaller than that seen in UPPS, which makes the C~55~ diphosphate used in bacterial cell wall biosynthesis (∼600 Å^3^ versus ∼900--1700 Å^3^, depending on the presence or absence of bound ligands, Figure [1](#fig1){ref-type="fig"}c and Figure S1c in the [SI](#notes-1){ref-type="notes"}). The Rv3378c protein thus adopts the same fold as seen in *cis*-head-to-tail prenyl diphosphate synthases, and this structure is unprecedented in enzymes involved in terpene biosynthesis. Attempts to obtain the structures of Rv3378c in the presence of its substrate TPP (by soaking and cocrystallization) were unsuccessful; therefore, we next used computational docking^[@ref17]^ to see how TPP might bind to Rv3378c, to guide the design of inactive mutants. The docking results obtained (Figure S2 in the [SI](#notes-1){ref-type="notes"}) indicated that the fused rings bound to a large hydrophobic pocket while the allyl side chain docked close to Y51 and Y90, suggesting that these residues might be involved in activating water molecules for nucleophilic attack at C13 and/or C15. To test this hypothesis, we made a Y51F mutant and a Y51F/Y90F double mutant, finding ∼13% and ∼5% wild-type activity, respectively, Figure S3 in the [SI](#notes-1){ref-type="notes"}. We then obtained structures of both mutants in the presence of TPP. In both, TPP occupies the polar-top/nonpolar-bottom cavity shown in Figure [1](#fig1){ref-type="fig"}b (Figure [2](#fig2){ref-type="fig"}a and Figure S4a in the [SI](#notes-1){ref-type="notes"}), with more complete electron densities found in the Y51F/Y90F double mutant (Figure [2](#fig2){ref-type="fig"}b and Figure S4b in the [SI](#notes-1){ref-type="notes"}, yellow) than in the Y51F single mutant (Figure S5 in the [SI](#notes-1){ref-type="notes"}), due presumably to more residual activity in the Y51F single mutant crystal. A similar though not identical hydrophobic pocket is occupied by *S*-*thiolo* farnesyl diphosphate (FSPP) when bound to UPPS, as illustrated in the superposition shown in Figure [2](#fig2){ref-type="fig"}b (FSPP in cyan). In UPPS, the two most conserved residues from a SCORECONS^[@ref18]^ analysis (which ranks residues in terms of their conserved nature) are D26 and R30 (Table S2 in the [SI](#notes-1){ref-type="notes"}) which in UPPS are involved in binding to Mg^2+^ and farnesyl diphosphate (FPP), facilitating diphosphate activation and removal. These two residues correspond to D34 and R38 in Rv3378c (a 2.2 Å Cα rmsd), and based on this homology to UPPS, might therefore be expected to play a role in diphosphate activation and release.

![Structures and activities of Rv3378c. (a) Rv3378c Y51F/Y90F double mutant structure with bound TPP. (b) Rv3378c/TPP (yellow, electron density contoured at 1.5σ) structure superimposed on *S*-*thiolo*-FSPP (cyan), bound to UPPS (PDB code 1X06). Mg^2+^ is from the UPPS structure. Catalytic residues in Rv3378c are shown with gray sticks. Y51, Y90 are based on the F51, F90 coordinates. (c) Activities of wild-type and Rv3378c mutants in TOH production and proposed catalytic mechanism for TOH formation. (d) Activities of wild-type and Rv3378c mutants in *iso*-TOH production and proposed catalytic mechanism for *iso*-TOH formation.](ja-2013-13127v_0003){#fig2}

To examine the role of these residues in catalysis, we mutated both to Ala. Activity results for these mutants together with Y51F, Y51F/Y90F, Y90F as well as the single DDXXD mutants reported previously^[@ref9]^ are shown in c and d of Figure [2](#fig2){ref-type="fig"} as well as in Figure S3 in the [SI](#notes-1){ref-type="notes"}. Whereas the WT protein has 41% *iso*-TOH activity and 59% TOH activity, D34A, R38A and Y90F mutants produced on average ∼1% *iso*-TOH but on average 49% TOH, meaning that D34, R38 and Y90 are all important for *iso*-TOH production, a more S~N~1-like reaction that requires D34 and R38 to facilitate dephosphorylation and carbocation formation, Figure [2](#fig2){ref-type="fig"}d. On the other hand, Y51 is involved in both TOH and *iso*-TOH formation since production of both is reduced in the Y51F mutant. In addition, the Y51F/Y90F double mutant has essentially no activity. Taken together, these results indicate that D34, R38, Y51 and Y90 are involved in 13*R*,13*S*-*iso*-tuberculosinol formation (Figure [2](#fig2){ref-type="fig"}d), while it is primarily Y51 that is involved in TOH formation, since both Y51F and the Y51F/Y90F mutants produce little or no TOH, as illustrated in Figure [2](#fig2){ref-type="fig"}c. The single DDXXD mutants have activities ranging from 32% to 53%, whereas the double Asp mutants are not active.^[@ref9]^ This suggests that the DDXXD motif, although not immediately adjacent to the active site, may also play a role in catalysis, perhaps by helping remove the Mg^2+^-PPi formed, since 2 Asps would be required for Mg^2+^ chelation.

Since Rv3378c is a target for antivirulence therapeutics, we were also interested in discovering Rv3378c inhibitors. We identified BPH-629 as one such inhibitor having a *K*~d~ ≈ 560 nM, Figure S6a in the [SI](#notes-1){ref-type="notes"}. Co-crystallization of Rv3378c and BPH-629 in the presence of Mg^2+^ yielded a complex structure containing two molecules of BPH-629 and one Mg^2+^ per Rv3378c monomer. Figure [3](#fig3){ref-type="fig"}a and Figure S7a in the [SI](#notes-1){ref-type="notes"} show the location of the inhibitor binding sites in the dimer. In each monomer, there are two bound BPH-629 molecules: one (BPH-629 (**1**)) is buried in the substrate binding site (Figure [3](#fig3){ref-type="fig"}b and Figure S7b in the [SI](#notes-1){ref-type="notes"}), the other (BPH-629 (**2**)) is located in the dimer interface, between a helix of monomer A and a loop of monomer B (a and b of Figure [3](#fig3){ref-type="fig"}). In both cases, the bisphosphonate head-groups chelate to a single Mg^2+^ that is in turn coordinated to the side chain of D34, Figure [3](#fig3){ref-type="fig"}c and Figure S7c in the [SI](#notes-1){ref-type="notes"}. Moreover, as shown in Figure [3](#fig3){ref-type="fig"}c, the side chain in BPH-629 (**1**) makes extensive nonpolar interactions with numerous hydrophobic amino acids in the TPP binding site, and BPH-629 (**2**) is sandwiched between the H41 of monomer A and Y259, S260, and L267 of monomer B.

![Inhibitor-bound structures of Rv3378c and DPPS. (a) Dimeric Rv3378c structure with two bound BPH-629 molecules (shown with spheres) in each monomer (four BPH-629 molecules in the dimer). Because there is only one molecule in an asymmetric unit, the dimer is constructed from the observed monomer structure and its symmetry partners. (b) Front view of Rv3378c dimer. Monomer A and monomer B are shown as a yellow cartoon and a pink surface, respectively. (c) Close-up view of the structure of Rv3378c bound to bisphosphonate inhibitor BPH-629 (thick orange sticks, electron densities contoured at 1.5σ). The BPH-629 molecules both coordinate to the catalytic Mg^2+^ (green sphere), which in turn coordinates to D34 (yellow sticks) from monomer A. BPH-629 (**1**) is buried in the substrate binding site in monomer A, formed by hydrophobic residues shown as orange lines. The hydrophobic moiety of BPH-629 (**2**) is stabilized by Y259, S260, and L267 from monomer B (magenta lines). (d) Dimeric DPPS structure with one bound BPH-640 molecule (shown as spheres) in each monomer. (e) Front view of DPPS dimer. Monomer A and monomer B are shown as a green cartoon and a cyan surface, respectively. (f) Close-up view of the structure of DPPS bound to bisphosphonate inhibitor BPH-640 (thick green sticks, electron densities contoured at 1.5σ). The hydrophobic moiety of BPH-640 is stabilized by residues from monomer A (green lines) and monomer B (cyan lines).](ja-2013-13127v_0004){#fig3}

Interestingly, a similar surface binding site is also found in *M. tuberculosis* DPPS (Rv2361c) in complex with another bisphosphonate, BPH-640, a close analogue of BPH-629, as shown in d, e, and f of Figure [3](#fig3){ref-type="fig"} and Figure S8a--c in the [SI](#notes-1){ref-type="notes"}. BPH-640 is a 410 nM inhibitor of DPPS (Figure S6b in the [SI](#notes-1){ref-type="notes"}) but lacks the O and CH~2~ groups present in BPH-629. Full crystallographic data acquisition and structure refinement details for this structure are shown in Table [1](#tbl1){ref-type="other"}, and electron density results are shown in Figure [3](#fig3){ref-type="fig"}f. As with BPH-629 (**2**), BPH-640 also occupies a dimer interface binding site, sandwiched between G77, N78, G79, R80, T83, R89, and R127 of monomer A and R292 and F293 of monomer B (Figure [3](#fig3){ref-type="fig"}f).

The results shown in Figure [3](#fig3){ref-type="fig"} indicate that the terpene synthase (phosphatase) Rv3378c and the *cis*-prenyl transferase DPPS both have the same overall fold. They both also exist as dimers in solution^[@ref9],[@ref19]^ as well as in crystals (a and d of Figure [3](#fig3){ref-type="fig"}), and both are inhibited by structurally similar bisphosphonates, with closely related binding modes (Figure [3](#fig3){ref-type="fig"}b and e) and similar affinities. These observations lead to the idea that in the future it may be possible to design multitarget inhibitors^[@ref20]−[@ref22]^ that target both enzymes in TB bacteria inside macrophages, inhibiting growth (DPPS/cell wall biosynthesis) as well as virulence (Rv3378c/tuberculosinol biosynthesis/invasion).

Summary {#sec4}
=======

We report the first structure of any bacterial diterpene synthase, tuberculosinol/*iso*-tuberculosinol synthase (Rv3378c) from *M. tuberculosis*, a target for anti-infective therapies that block virulence factor formation. This phosphatase adopts the same fold as found in the *Z*- or *cis*-prenyltransferases. We also obtained structures in the presence of TPP and with a bisphosphonate inhibitor where one molecule occupied the TPP substrate binding site; the second is located at the dimer interface site. An unusual surface site was also found with a related bisphosphonate inhibitor bound to the *M. tuberculosis* DPPS (Rv2361c). In addition, we used the X-ray structures of Rv3378c together with the results of site-directed mutagenesis to propose mechanisms of action for formation of tuberculosinol and the *iso*-tuberculosinols in which two Tyr residues play an important role. Given the similarity in local and global structures of Rv3378c and Rv2361c, the possibility exists that in the future it might be possible to develop multitarget inhibitors that target not only virulence, but also cell wall biosynthesis, in part based on the structures reported here.

Experimental materials, methods, supporting tables and figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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